Abstract
In this work, the stability of Bevacizumab (Avastin®) repackaged in individual 1 mL single-use syringes and stored at different conditions was assessed. Bevacizumab repackaged in single-use syringes results from the off-label use of the drug as an intravitreal agent in the treatment of retinal diseases. Bevacizumab stability was assessed by assaying the anti-VEGF activity using an indirect ELISA method and a Dynamic Light Scattering study. The thermal stability of the drug was also studied by calorimetric analysis, aimed to evaluate thermodynamic parameters associated to the thermal unfolding process. Furthermore, microbiological and fungal tests on the Bevacizumab syringes were performed. As a result, a significant decrease of the anti-VEGF activity was detected when syringes were exposed to UV light at a temperature of 37°C. Under these conditions, the Dynamic Light Scattering study showed an increase of the average size of Bevacizumab; probably due to aggregation. In conclusion, Bevacizumab stability, when stored under different conditions, was assessed considering three different aspects: anti-VEGF activity, microbial contamination and physico-chemical properties. Bevacizumab was found to be stable, under sterile conditions, for 3 months at 4°C and for 7 days at room temperature, exposed to indirect light sources, while a brief exposure of the drug to direct UV radiation proved detrimental to drug stability.
Keywords: Anti-VEGF activity, Bevacizumab, Bevacizumab stability, calorimetric studies, dynamic light scattering, repackaged Bevacizumab, microbiological assay, immunoassay.
Current Pharmaceutical Biotechnology
Title:Quantification, Microbial Contamination, Physico-chemical Stability of Repackaged Bevacizumab Stored Under Different Conditions
Volume: 15 Issue: 2
Author(s): Leonarda Signorello, Stefania Pucciarelli, Giulia Bonacucina, Valeria Polzonetti, Marco Cespi, Diego R. Perinelli, Giovanni F. Palmieri, Riccardo Pettinari, Claudio Pettinari, Giovanni Fiorentini and Silvia Vincenzetti
Affiliation:
Keywords: Anti-VEGF activity, Bevacizumab, Bevacizumab stability, calorimetric studies, dynamic light scattering, repackaged Bevacizumab, microbiological assay, immunoassay.
Abstract: In this work, the stability of Bevacizumab (Avastin®) repackaged in individual 1 mL single-use syringes and stored at different conditions was assessed. Bevacizumab repackaged in single-use syringes results from the off-label use of the drug as an intravitreal agent in the treatment of retinal diseases. Bevacizumab stability was assessed by assaying the anti-VEGF activity using an indirect ELISA method and a Dynamic Light Scattering study. The thermal stability of the drug was also studied by calorimetric analysis, aimed to evaluate thermodynamic parameters associated to the thermal unfolding process. Furthermore, microbiological and fungal tests on the Bevacizumab syringes were performed. As a result, a significant decrease of the anti-VEGF activity was detected when syringes were exposed to UV light at a temperature of 37°C. Under these conditions, the Dynamic Light Scattering study showed an increase of the average size of Bevacizumab; probably due to aggregation. In conclusion, Bevacizumab stability, when stored under different conditions, was assessed considering three different aspects: anti-VEGF activity, microbial contamination and physico-chemical properties. Bevacizumab was found to be stable, under sterile conditions, for 3 months at 4°C and for 7 days at room temperature, exposed to indirect light sources, while a brief exposure of the drug to direct UV radiation proved detrimental to drug stability.
Export Options
About this article
Cite this article as:
Signorello Leonarda, Pucciarelli Stefania, Bonacucina Giulia, Polzonetti Valeria, Cespi Marco, Perinelli R. Diego, Palmieri F. Giovanni, Pettinari Riccardo, Pettinari Claudio, Fiorentini Giovanni and Vincenzetti Silvia, Quantification, Microbial Contamination, Physico-chemical Stability of Repackaged Bevacizumab Stored Under Different Conditions, Current Pharmaceutical Biotechnology 2014; 15 (2) . https://dx.doi.org/10.2174/1389201015666140619120834
DOI https://dx.doi.org/10.2174/1389201015666140619120834 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Association of Val16Ala Polymorphism of Manganese Superoxide Dismutase
(MnSOD) with Food Intake and Cardiometabolic Risk Factors in
the Elderly in Primary Care in Porto Alegre
Current Aging Science Type 2 Diabetes Mellitus and Invokana: An FDA Approved Drug
Current Diabetes Reviews Antiproliferative Effect of HSP90 Inhibitor Y306zh Against Pancreatic Cancer is Mediated by Interruption of AKT and MAPK Signaling Pathways
Current Cancer Drug Targets NAD<sup>+</sup>-Dependent Enzymes at the Endoplasmic Reticulum
Current Topics in Medicinal Chemistry Bisphosphonate Therapy for Patients with Breast Cancer
Current Cancer Therapy Reviews Pioglitazone Therapy Decreases Bone Mass Density and Increases Fat Mass: A Meta-Analysis
Current Pharmaceutical Design Electroporation Advances in Large Animals
Current Gene Therapy Carnosine and Kidney Diseases: What We Currently Know?
Current Medicinal Chemistry Experimental Brain Ischemic Preconditioning: A Concept to Putative Targets
CNS & Neurological Disorders - Drug Targets Endothelin Receptors, Mitochondria and Neurogenesis in Cerebral Ischemia
Current Neuropharmacology Chemotherapy and Delivery in the Treatment of Primary Brain Tumors
Current Clinical Pharmacology Mononuclear Phagocyte Accumulation in Visceral Tissue in HIV Encephalitis: Evidence for Increased Monocyte/Macrophage Trafficking and Altered Differentiation
Current HIV Research Chromatin Remodeling, DNA Damage Repair and Aging
Current Genomics Microaspiration in Intubated Critically Ill Patients: Diagnosis and Prevention
Infectious Disorders - Drug Targets Curcumin Activates the Nrf2 Pathway and Induces Cellular Protection Against Oxidative Injury
Current Molecular Medicine Adrenomedullin and Nitric Oxide: Implications for the Etiology and Treatment of Primary Brain Tumors
CNS & Neurological Disorders - Drug Targets Pharmaceutical Targeting of the Brain
Current Pharmaceutical Design A Critical Review of Laboratory-Based Studies Examining the Relationships of Social Anxiety and Alcohol Intake
Current Drug Abuse Reviews L-Dopa Prodrugs: An Overview of Trends for Improving Parkinsons Disease Treatment
Current Pharmaceutical Design Effects of Simvastatin on the Metabolism of Fatty Acids in Combined Secondary Prevention of Coronary Heart Disease: Dosage and Gender Differences between the Effects
Cardiovascular & Hematological Disorders-Drug Targets